[Allogeneic bone marrow transplantation in the treatment of acute leukemias of children. Study of 26 patients]

Arch Fr Pediatr. 1986 Dec;43(10):769-74.
[Article in French]

Abstract

Twenty-six children with acute leukemia were treated with allogeneic marrow transplantation from HLA identical siblings after a conditioning regimen with Cyclophosphamide-total body irradiation (19 patients), Melphalan-total body irradiation (6 patients) or Busulfan-cyclophosphamide (1 patient). Eighteen were transplanted in complete remission (4 with acute non lymphoblastic leukemia in first remission, 14 with acute lymphoblastic leukemia: 6 in first, 6 in second and 2 in subsequent remission): 2 died of cytomegalovirus pneumoniae, 1 relapsed and 15 survive in continuous complete remission from 5 to 42 months after transplantation (median = 22 months). Eight were transplanted in relapse, 7 achieve complete remission, 5 of them relapsed, 1 died of G.V.H. and 1 survives in continuous complete remission 46 months after transplantation. Actuarial analysis shows a disease free survival rate at 3 years of 82% for patients transplanted in remission and 12% for patients transplanted in relapse (p less than 0.01).

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adolescent
  • Bone Marrow Transplantation*
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Cyclophosphamide / therapeutic use
  • Female
  • Humans
  • Leukemia / drug therapy
  • Leukemia / radiotherapy
  • Leukemia / therapy*
  • Male
  • Melphalan / therapeutic use
  • Whole-Body Irradiation

Substances

  • Cyclophosphamide
  • Melphalan